|
Patent landscape, scope, and claims: |
Scope and Patent Landscape for U.S. Patent 6,121,314 (Topical Composition with “Formula I” Active and Lower Alkanol)
U.S. Patent 6,121,314 claims a topical pharmaceutical composition that fixes three core claim anchors: (1) a specific “compound of formula I” as the active, (2) a “lower alkanol” as a required component, and (3) defined solvent/water/alcohol ranges and selected excipient and delivery-form options. Independent claim 1 is composition-focused and broad on the active and solvent system, while dependent claims narrow to water and ethanol, water and alcohol percentage windows, “substantially free of fatty material,” non-anionic surfactants, antifungal treatment use, and specific solubilizing/oil phases (including polyoxyethylene fatty alcohol ethers and isopropyl myristate) plus quantitative ratio limits. A process claim and a method-of-use claim extend enforcement into preparation and administration for fungal infections.
Key claim architecture in U.S. Patent 6,121,314
What is the independent claim protecting?
- Claim 1: a topical pharmaceutical composition with:
- Active agent: “a compound of formula I” (structure defined by the patent’s Formula I placeholder).
- Vehicle component: a lower alkanol.
- This independent claim sets a baseline infringement theory for any topical antifungal product that uses the same formula-I active and includes a lower alkanol in the composition.
How do the dependent claims narrow the protected space?
- Water content and alcohol content ranges
- Claim 2: contains water
- Claim 3: 50–85% water
- Claim 4: 5–35% lower alkanol
- Claim 5: alkanol is ethanol
- Excipients and purity constraints
- Claim 6: substantially free of fatty material
- Claim 7: includes a non-anionic surfactant
- Indication, delivery form, and antifungal use
- Claim 8: treatment of fungal infections
- Claim 9: formulation is spray, gel, or fluid gel
- Claim 10: solubilizing agent is polyoxyethylene fatty alcohol ether
- Claim 11: ratio of formula-I compound to solubilizing agent ~1:0.5 to 1:15
- Alternative excipient architecture with an oil phase
- Claim 12: includes an oil phase plus excipients
- Claim 13: oil phase is isopropyl myristate
- Claim 14: formula-I compound to oil phase ~1:5 to 1:40 (w/w)
- Active loading range
- Claim 15: formula-I compound present 0.1–5% (w/w)
What additional protection exists beyond product composition?
- Process claim
- Claim 16: a preparation process that works up formula-I compound with a lower alkanol and adds further excipients.
- Method of use
- Claim 17: administering a pharmaceutically effective amount of claim-1 composition to treat fungal infections.
What patents protect topical antifungal compositions with a specific “formula I” compound and lower alkanol in the US?
Claim coverage map by element (infringement “building blocks”)
To infringe claim 1, a product must have:
- A topical pharmaceutical composition
- Active agent = formula I compound
- Contains a lower alkanol
Dependent claims then add more requirements for narrower coverage:
- Water-heavy systems: claim 2–3
- Ethanol-specific: claim 5
- Alcohol loading range: claim 4
- Fatty-material exclusion: claim 6
- Non-anionic surfactant inclusion: claim 7
- Antifungal treatment use: claim 8
- Delivery form: claim 9
- Solubilizer identity and ratio: claim 10–11
- Oil phase architecture: claim 12–14
- Active loading: claim 15
Practical enforcement leverage
- Broader infringement entry point: claim 1.
- Higher-risk-to-generic design-around vectors: alcohol identity (ethanol), water/alcohol windows, “substantially free of fatty material,” and the explicit excipient identity/ratio ranges (polyoxyethylene fatty alcohol ether; isopropyl myristate).
Adjacent scope questions to consider
- Whether a competitor can avoid claim 1 by:
- Using a different alcohol (e.g., not a “lower alkanol” under the patent’s definition).
- Using no lower alkanol.
- Using a different active (a different substitution pattern outside formula I).
- Using a different topical vehicle not meeting “composition comprising” lower alkanol.
How broad are the composition claims for U.S. 6,121,314?
Claim 1 breadth drivers
- The active is locked to formula I but the dependent claims do not further restrict active identity beyond free base vs acid addition salt in the antifungal use claim.
- “Lower alkanol” is broad in concept; the dependent claims add ethanol as an explicit option but claim 1 itself does not require ethanol.
- “Topical pharmaceutical composition” is broad as to form factor unless a competitor chooses to match dependent-claim delivery forms (spray/gel/fluid gel).
Claim 2–7 narrowers (solvent and excipient constraints)
- Claim 2 and 3 impose very high water content (50–85%).
- Claim 4 limits lower alkanol to 5–35%, which is a meaningful design constraint for formulations that use alcohol as a major cosolvent.
- Claim 6 “substantially free of fatty material” creates a formulation boundary that is often litigated as a factual/quantitative question depending on how “fatty material” is defined in the patent and measured in the accused product.
- Claim 7 requires non-anionic surfactant, which prevents competitors from using cationic or amphoteric surfactants if they want to stay within the dependent claim.
Claim 8–11 narrowers (antifungal use + solubilizing architecture)
- Claim 8 adds indication and formulation components: solubilizing agent + excipients “as appropriate.”
- Claim 10 identifies the solubilizer as polyoxyethylene fatty alcohol ether. If a competitor uses a different solubilizer class (e.g., polysorbate, PEG ethers with different chain structures, cyclodextrins), that can avoid the dependent coverage even if claim 1 could still read.
- Claim 11 sets a quantitative ratio window (1:0.5 to 1:15 compound-to-solubilizer), which is another high-specificity design target.
Claim 12–14 narrowers (oil phase architecture)
- Claim 12 requires an oil phase architecture.
- Claim 13 fixes isopropyl myristate as the oil phase for that dependent claim.
- Claim 14 provides 1:5 to 1:40 (w/w) compound-to-oil-phase. This is a precise formulation ratio and provides a strong boundary for a design-around that preserves formula-I active and includes oil but changes the oil identity or ratio.
Claim 15 loading window
- 0.1–5% (w/w) active is an enforceable constraint for claim coverage if a competitor markets a higher- or lower-loading product.
Which “sub-formulas” or salt forms are within the scope of claim 8 (free base vs acid addition salt)?
How salt form enters the claim set
- Claim 8 specifies the formula-I compound can be:
- free base, or
- acid addition salt
- This prevents a design-around that tries to claim “we use a different acid salt but it’s outside the claim.” As long as it remains an acid addition salt of the formula-I compound, dependent coverage remains.
What a competitor can still do
- Avoidance is more likely via:
- Using a different chemical entity outside formula I.
- Avoiding lower alkanol inclusion (claim 1).
- Avoiding water/alcohol windows or fatty-material conditions (claims 2–7) depending on which dependent claims are asserted.
- Using different solubilizer/oil phase components outside claim 10/13 (dependent claims) while still potentially falling under claim 1.
What formulations are protected by U.S. 6,121,314 (spray, gel, fluid gel; water-heavy vs oil-phase)?
Two main formulation archetypes in the claim set
- Water + lower alkanol systems (aqueous/alcohol cosolvent)
- Claims 2–4, and optionally 5, 6, 7, 15
- Claim 3 is especially specific: 50–85% water.
- Solubilizer-driven systems and delivery forms for antifungal treatment
- Claims 8–11 and 9
- Claim 10 is solubilizer identity: polyoxyethylene fatty alcohol ether.
- Oil-phase systems
- Claims 12–14
- Isopropyl myristate is explicitly claimed as the oil phase in claim 13.
Product-design risk for sponsors and generics
- If an accused generic product uses:
- the formula-I active, and
- any lower alkanol,
- it starts at claim 1 risk level.
- If it also matches water and alcohol ranges, non-anionic surfactants, and antifungal delivery form, it moves into multiple dependent-claim risks.
- If it matches polyoxyethylene fatty alcohol ether solubilization or isopropyl myristate oil phase, dependent-claim risk increases materially.
How does the patent constrain ethanol-based antifungal topical products (claim 5 and water/alcohol windows)?
Ethanol-specific claim
- Claim 5: alkanol is ethanol.
- That makes ethanol-based compositions more difficult to design around if they also satisfy claim 1 and related dependent claim constraints (water content, alcohol range, etc.).
Water-alcohol window constraints
- Water: 50–85% (claim 3)
- Lower alkanol: 5–35% (claim 4)
These are key numeric constraints:
- A formulation with lower water content or lower/higher alcohol loading can avoid claims 2–4 but may still remain exposed under claim 1 unless the alcohol is removed or the active is changed.
What about “substantially free of fatty material” and non-anionic surfactants (claims 6–7)?
Fatty-material restriction
- Claim 6 limits the formulation to being “substantially free of fatty material.”
- This term can be a factual battleground: competitors can reduce fatty excipients, but if the accused formulation contains fatty substances used as emollients, oils, or ester-based components, the “substantially free” criterion becomes central to infringement analysis.
Non-anionic surfactant requirement
- Claim 7 specifies a non-anionic surfactant.
- If a competitor uses an anionic surfactant (e.g., typical anionic emulsifiers), it can target a design-around for claim 7 while leaving claim 1 intact if lower alkanol and the formula-I active remain.
When does U.S. Patent 6,121,314 lose exclusivity for topical antifungals (expiration and term drivers)?
No expiration timing can be produced from the claim text alone. The enforceable end date depends on:
- the patent’s filing date and issuance details,
- any patent term adjustment,
- any terminal disclaimer,
- and whether any related filings affect continuation chains.
How strong is the patent estate for U.S. Patent 6,121,314 (claim validity and design-around resistance)?
Strength indicators in the claim structure
- Claim 1 ties infringement to a specific active (formula I) and a required solvent class (lower alkanol). That is a relatively direct linkage that limits the universe of non-infringing alternatives if a product must remain topical and must use lower alkanol.
- Multiple dependent claims lock in narrow excipient identities and quantitative ratio windows (polyoxyethylene fatty alcohol ether and isopropyl myristate), creating additional “fall-through” coverage even if a competitor changes one formulation aspect.
Design-around opportunities implied by the claim set
- Removing lower alkanol (or replacing it with something that does not qualify as a “lower alkanol” under the patent’s definition) is the cleanest conceptual exit from claim 1.
- Swapping solubilizer class or oil phase identity can avoid dependent claims 10 and 13 even if claim 1 is still potentially in play.
- Adjusting active loading out of 0.1–5% (claim 15) is another boundary line.
What generic entry risks exist for products that target the same antifungal indication using lower alkanols?
Risk matrix by product similarity
- High risk if the generic:
- uses the formula-I active, and
- uses a lower alkanol vehicle,
- and markets topical antifungal therapy with similar solubilizer or oil-phase architecture.
- Moderate risk if the generic:
- uses the formula-I active and lower alkanol,
- but differs in water/alcohol ranges, delivery form, or surfactant type so fewer dependent claims are met.
- Lower risk if the generic:
- omits lower alkanol entirely, or
- uses a different active not within formula I.
What patent litigation affects U.S. Patent 6,121,314 (ANDA/Paragraph IV or state cases)?
No litigation docket information is provided in the claim excerpt. A litigation landscape cannot be produced without case records tied to this specific patent number.
What is the Orange Book status of U.S. Patent 6,121,314?
The claim text does not indicate Orange Book listing status. Orange Book status requires FDA product and patent listing data for the specific NDA or ANDA reference drug.
Which companies are challenging or licensing around U.S. Patent 6,121,314?
No assignee, license, settlement, or challenger list is included in the provided information. Company-level landscape cannot be produced from the claim excerpt alone.
How does U.S. 6,121,314 compare with neighboring patents for the same topical antifungal active?
A comparison requires:
- identification of the formula-I active,
- related continuation patents,
- and third-party patents covering similar excipient vehicles and antifungal formulations.
The formula-I structure is not reproduced here, so comparative scoping cannot be completed.
Key Takeaways
- Claim 1 is the central hook: topical composition with formula-I active + lower alkanol.
- Dependent claims stack multiple formulation constraints that can multiply infringement exposure: water and alcohol ranges, ethanol option, “substantially free of fatty material,” non-anionic surfactant, antifungal use, delivery forms, specific solubilizer (polyoxyethylene fatty alcohol ether) with compound-to-solubilizer ratios, and specific oil phase (isopropyl myristate) with compound-to-oil ratios.
- Process (claim 16) and method-of-use (claim 17) expand enforcement beyond the packaged product to manufacture and administration for fungal infections.
- Design-around strategy most implicated by the claim set is removal or substitution of the lower alkanol; secondary strategies include altering water/alcohol windows, excluding fatty materials, changing surfactant class, and switching solubilizer/oil phase identities and ratios.
FAQs
- If a topical product uses the formula-I active but uses propylene glycol instead of ethanol, does it avoid claim 5?
- Can a formulation that includes an anionic surfactant still infringe claim 1 even if it misses claim 7?
- If an accused product matches the solubilizer type (polyoxyethylene fatty alcohol ether) but uses a compound-to-solubilizer ratio outside 1:0.5 to 1:15, which claim set remains at risk?
- Does including isopropyl myristate as an oil phase automatically place a product within claim 13, or must it also meet the ratio window in claim 14?
- How do changes to active loading outside 0.1–5% (w/w) affect exposure under claim 15 while still meeting claim 1?
References
- U.S. Patent 6,121,314 (claims as provided by user).
More… ↓
⤷ Start Trial
|
